Skip to main content
Multiple Sclerosis Discovery Forum
Inspiring Connections
Utility Navigation
Feedback
Newsletter
RSS
Twitter
User Top Menu
Welcome, guest
Log In
Join
Why Join?
Search form
Search
About Us
Overview
Who We Are
Contact
Fan Mail
How to Cite
News & Future Directions
New Findings
News Briefs
Podcasts
News Synthesis
Essays & Opinions
Blogs
Papers
Editors' Picks
Classic Papers
Archive
Forums
Discussions
Webinars
Professional Resources
Meetings & Events
Past Meetings
Funding Opportunities
Jobs
Member Directory
Bulletin Board
Useful Links
Research Resources
Data Visualizations
Clinical Trials - Public Availability of Results
World Map
MS trials baseline
NMO History
NMO Galaxy
Map of MS Prevalence
Progressive MS Authors Galaxy
Word Cloud
MSLine
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Symptoms Prevalence
Scientific Literature TreeMap
Clinical Trials in MS
Drug-Development Pipeline
Tissue Repositories
MSGene
Animal Models
Clinical Trials
Click Here to Support MSDF
You are here
Home
Most Viewed
Novartis gains FDA approval for Gilenya(TM), a novel first-line multiple sclerosis treatment shown to significantly reduce relapses and delay disability progression
Cyclophosphamide for multiple sclerosis.
The Role of Demyelination in Neuromyelitis Optica Damage: Diffusion-Tensor MR Imaging Study.
Rehabilitation in transverse myelitis.
Assessing the potential impact of non-proprietary drug copies on quality of medicine and treatment in patients with relapsing multiple sclerosis: the experience with fingolimod.
Can we overcome the 'clinico-radiological paradox' in multiple sclerosis?
Characterization of natural killer cells in paired CSF and blood samples during neuroinflammation.
Granzyme B-Induced Neurotoxicity Is Mediated via Activation of PAR-1 Receptor and Kv1.3 Channel.
Progressive multifocal leukoencephalopathy: new concepts.
Immunopathology of multiple sclerosis.
Effect of intramuscular interferon beta-1a on gray matter atrophy in relapsing-remitting multiple sclerosis: A retrospective analysis.
The EDSS-Plus, an improved endpoint for disability progression in secondary progressive multiple sclerosis.
Long-term efficacy, tolerability and retention rate of azathioprine in 103 aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder patients: a multicentre retrospective observational study from the UK.
Endogeneous Remyelination: Findings in Human Studies.
B-Cell Depletion Abrogates T Cell-Mediated Demyelination in an Antibody-Nondependent Common Marmoset Experimental Autoimmune Encephalomyelitis Model.
Neurorehabilitation for other neurologic disorders.
Autonomic dysfunction: A unifying multiple sclerosis theory, linking chronic cerebrospinal venous insufficiency, vitamin D(3), and Epstein-Barr virus.
The cost of multiple sclerosis drugs in the US and the pharmaceutical industry: Too big to fail?
Contactin-1 IgG4 antibodies cause paranode dismantling and conduction defects.
Exploring the human tear fluid: discovery of new biomarkers in multiple sclerosis.
Long-term protection of central axons with phenytoin in monophasic and chronic-relapsing EAE.
Inhibition by riluzole of electrophysiological responses mediated by rat kainate and NMDA receptors expressed in Xenopus oocytes.
Correction: Adherence to Interferon β-1b Treatment in Patients with Multiple Sclerosis in Spain.
The next generation of exoskeletons: lighter, cheaper devices are in the works.
No increase in cancer incidence detected after cyclophosphamide in a French cohort of patients with progressive multiple sclerosis.
Pages
« first
‹ previous
…
177
178
179
180
181
182
183
184
185
…
next ›
last »